CRANBURY, NJ (CBS Baltimore) — Prinston Pharmaceutical Inc. has voluntarily recalled one lot of Irbesartan and seven lots of Irbesartan HCTZ Tablets due to a detection of trace amount of an unexpected impurity found in an ingredient.
Prinston is only recalling lots of Irbesartan-containing products that contain Nnitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.READ MORE: Campaign 2021: Polls Open For Early Voting In New York City Primaries; First With Ranked Choice Voting
“N-nitrosodiethylamine (NDEA) is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification,” the company said in a press release on Jan. 18.
The company has not received any reports of adverse reactions related to the drug.READ MORE: NYPD: Suspects Demand Cash, Grab Jewish Man's Yarmulke In Brooklyn Robbery
Irbesartan and Irbesartan HCTZ are used to control high blood pressure and for treatment of heart failure.
Patients should contact their doctors if they were prescribed the drug and get an alternative treatment.MORE NEWS: New York-Presbyterian To Mandate COVID-19 Vaccinations For Staff
For a full list of the drugs recalled, click here: Irbesartan recall